Denisa Bogdan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.

Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.

Journal: European urology
Published: August 07, 2026

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Journal: Investigational new drugs
Published: February 04, 2026

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 24, 2025

Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis.

Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis.

Journal: Signal transduction and targeted therapy
Published: September 24, 2025

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Journal: The Journal of clinical investigation
Published: July 23, 2025

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

Journal: The Journal of clinical investigation
Published: July 22, 2025

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.

Journal: iScience
Published: January 27, 2025

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2024

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Journal: Oncogene
Published: June 24, 2024

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Journal: Cancer cell
Published: April 12, 2024

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

Journal: Nature communications
Published: March 07, 2024
Showing 1-12 of 27

Last Updated: 09/26/2026